Gerburg M Wulf
Overview
Explore the profile of Gerburg M Wulf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2886
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lei J, Dobrolecki L, Huang C, Srinivasan R, Vasaikar S, Lewis A, et al.
bioRxiv
. 2024 Dec;
PMID: 39713418
Combination chemotherapy remains essential for clinical management of triple-negative breast cancer (TNBC). Consequently, responses to multiple single agents cannot be delineated at the single patient level, even though some patients...
2.
Mohd O, Heng Y, Wang L, Thavamani A, Massicott E, Wulf G, et al.
Anal Chem
. 2024 Jul;
96(31):12729-12738.
PMID: 39044395
MicroRNAs (miRNAs) are small RNAs that are often dysregulated in many diseases, including cancers. They are highly tissue-specific and stable, thus, making them particularly useful as biomarkers. As the spatial...
3.
Heng Y, Baker G, Fein-Zachary V, Guzman-Arocho Y, Bret-Mounet V, Massicott E, et al.
Breast Cancer Res
. 2024 Jul;
26(1):109.
PMID: 38956693
Background: The effect of gender-affirming testosterone therapy (TT) on breast cancer risk is unclear. This study investigated the association between TT and breast tissue composition and breast tissue density in...
4.
5.
Guo Z, Luo J, Mashl R, Hoog J, Maiti P, Fettig N, et al.
Cancer Res Commun
. 2024 May;
4(6):1430-1440.
PMID: 38717161
Significance: In this research, we demonstrated that the pan-PI3K inhibitor copanlisib enhanced the cytotoxicity of eribulin in a panel of TNBC PDX models. The improved tumor growth inhibition was irrespective...
6.
Ke S, Dang F, Wang L, Chen J, Naik M, Li W, et al.
Nat Commun
. 2024 Apr;
15(1):3220.
PMID: 38622115
Induced oncoproteins degradation provides an attractive anti-cancer modality. Activation of anaphase-promoting complex (APC/C) prevents cell-cycle entry by targeting crucial mitotic proteins for degradation. Phosphorylation of its co-activator CDH1 modulates the...
7.
Heng Y, Baker G, Fein-Zachary V, Guzman-Arocho Y, Bret-Mounet V, Massicott E, et al.
medRxiv
. 2024 Jan;
PMID: 38260574
Objective: Determine the association between TT and breast tissue composition and breast tissue density in trans masculine individuals (TMIs). Design: This is a cross-sectional study. Setting: TMIs (n=444) underwent chest-contouring...
8.
Patterson-Fortin J, Jadhav H, Pantelidou C, Phan T, Grochala C, Mehta A, et al.
Nat Commun
. 2023 Dec;
14(1):8193.
PMID: 38081854
No abstract available.
9.
Batalini F, Madison R, Sokol E, Jin D, Chen K, Decker B, et al.
JCO Precis Oncol
. 2023 Nov;
7:e2300091.
PMID: 37992259
Purpose: Poly ADP-ribose polymerase inhibitors (PARPi) are approved for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer (mBC) and germline pathogenic/likely pathogenic variant (hereafter mutation) in the...
10.
Varkaris A, Fece de la Cruz F, Martin E, Norden B, Chevalier N, Kehlmann A, et al.
Cancer Discov
. 2023 Nov;
14(2):227-239.
PMID: 37916958
Significance: In one of the largest patient cohorts analyzed to date, this study defines the clinical landscape of acquired resistance to PI3Kα inhibitors. Genomic alterations within the PI3K pathway represent...